Share:
House Co-Sponsorship Memoranda
House of Representatives
Session of 2023 - 2024
Regular Session
MEMORANDUM
| Posted: | June 26, 2023 10:31 AM |
|---|---|
| From: | Representative Russ Diamond |
| To: | All House members |
| Subject: | Metastatic Breast Cancer Awareness Day Resolution |
| I plan to introduce a resolution recognizing October 13, 2023 as “Metastatic Breast Cancer Awareness Day” in Pennsylvania. Metastatic breast cancer, also called stage IV or advanced breast cancer, is not a specific type of breast cancer, but rather the most advanced stage of breast cancer. Metastatic breast cancer is breast cancer that has spread beyond the breast to other organs in the body (most often the bones, lungs, liver or brain). Much of the talk around breast cancer focuses on early detection and routine diagnosis, where we have seen tremendous progress in the last 30 years; however, the story for advanced disease is quite different. Metastatic breast cancer patients continue to face many unique challenges, such as the emotional and physical demands of continual treatment. Currently no cure exists for metastatic breast cancer and those with metastatic breast cancer will continue treatment indefinitely with the goal of extending the best quality life possible. More than one in eight women and one in 833 men in the U.S. will be diagnosed with breast cancer in their lifetimes. In 2023, an estimated 300,590 Americans will be diagnosed with an invasive form of breast cancer. Metastatic breast cancer cuts short the life expectancy of too many people in Pennsylvania leaving a lasting effect on their families. It is important that we recognize the need for an additional focus on the personal and social burdens of metastatic breast cancer, the needs of the patient, and promising research efforts in the development of more effective treatments. I ask that you join me in co-sponsoring this resolution to raise awareness and show your support for our family members, neighbors, friends and colleagues affected by metastatic breast cancer. |
Introduced as HR164